Effect of combined magnesium and vitamin E supplementation in treatment of women with polycystic ovary syndrome

Phase 3

• Conditions: Polycystic ovary syndrome.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT2017090133941N18
• Lead Sponsor: Vice chancellor for research, Arak University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 October 2019

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

Patients with polycystic ovary syndrome aged 18 to 40 years

Exclusion Criteria

The intake of magnesium and vitamin E supplements within the past 3 months
Metabolic disorders

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Calculation using HOMA formula.

Secondary Outcome Measures

Name	Time	Method
Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;LDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;FPG. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.